The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension
Authors' conclusion
These findings suggest that in contrast to the largely maintained gains in dual-energy X-ray absorptiometry (DXA)-derived spine and hip BMD, a single dose of ZOL was not as effective in maintaining the gains in volumetric peripheral bone density and microarchitecture produced by 15 months of overlapping treatment with denosumab and teriparatide.
Study context
- Population
- Postmenopausal women with osteoporosis previously treated with 9 months of teriparatide (20-μg or 40-μg daily) overlapped with denosumab (60 mg at months 3 and 9) in the DATA-HD study76 randomized in DATA-HD
- Participants
- 53 women
- Primary endpoint
- Volumetric BMD and microarchitecture at distal radius and tibia by HR-pQCT
- Follow-up
- Months 27 and 42
Methodological detailssingle-group extension, HR-pQCT
- Single-group extension
- HR-pQCT
Primary result
As reported in the abstract
Peripheral volumetric BMD, microarchitecture and strength after ZOL · 27 months post-ZOL
- Total and cortical bone mineral density (BMD) gradually decreased over 27 months; values similar to baseline at radius but still significantly above baseline at tibia
- Cortical porosity decreased below pretreatment baseline at month 27 at both sites, then increased from month 27 to 42
- No significant changes in trabecular parameters throughout the 27-month post-ZOL period
- Stiffness and failure load decreased progressively from month 15 to 42 at both sites, though remained above baseline at tibia
Original publication
The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension. J Bone Miner Res. Published 5 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →